Why Did HealthEquity Stock Fall So Much?
HealthEquity (NASDAQ:HQY) is a fintech company that acts as an…
Sell
40
AVDL Quote, Financials, Valuation and Earnings
Last price:
$8.11
Seasonality move
:
7.32%
Day range:
$8.00 - $8.29
52-week range:
$7.39 - $19.09
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
4.57x
P/B ratio:
10.62x
Volume:
491.8K
Avg. volume:
1.1M
1-year change:
-51.78%
Market cap:
$784.6M
Revenue:
$169.1M
EPS (TTM):
-$0.52
Analysts' Opinion
-
Consensus RatingAvadel Pharmaceuticals PLC has received a consensus rating of Buy. The company's average rating is a Buy based on 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $17.70, Avadel Pharmaceuticals PLC has an estimated upside of 117.98% from its current price of $8.12.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $13.00 representing 100% downside risk from its current price of $8.12.
Fair Value
-
According to the consensus of 7 analysts, Avadel Pharmaceuticals PLC has 117.98% upside to fair value with a price target of $17.70 per share.
AVDL vs. S&P 500
-
Over the past 5 trading days, Avadel Pharmaceuticals PLC has underperformed the S&P 500 by -6.77% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Avadel Pharmaceuticals PLC does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Avadel Pharmaceuticals PLC has grown year-over-year revenues for 3 quarters straight. In the most recent quarter Avadel Pharmaceuticals PLC reported revenues of $50.4M.
Earnings Growth
-
Avadel Pharmaceuticals PLC earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Avadel Pharmaceuticals PLC reported earnings per share of -$0.05.
Enterprise value:
710.9M
EV / Invested capital:
9.63x
Price / LTM sales:
4.57x
EV / EBIT:
--
EV / Revenue:
4.20x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-15.15x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$153.8M
Return On Assets:
-30.05%
Net Income Margin (TTM):
-28.88%
Return On Equity:
-63.43%
Return On Invested Capital:
-63.43%
Operating Margin:
-6.54%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | $169.1M | $19.5M | $50.4M | |
| Gross Profit | -- | $27.1M | $153.8M | $18.8M | $45.6M | |
| Operating Income | -$95.2M | -$137.8M | -$42.4M | -$24.9M | -$3.3M | |
| EBITDA | -$97.6M | -$149.1M | -$35.6M | -$26.5M | -$1.6M | |
| Diluted EPS | -$2.29 | -$2.01 | -$0.52 | -$0.29 | -$0.05 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $263.5M | $192.5M | $100.8M | $134.2M | $134.2M | |
| Total Assets | $311.6M | $247.3M | $132.8M | $164.7M | $164.2M | |
| Current Liabilities | $15.1M | $21M | $55.8M | $36.9M | $48.8M | |
| Total Liabilities | $149.4M | $169M | $153.9M | $77M | $90.4M | |
| Total Equity | $162.3M | $78.2M | -$21.1M | $87.7M | $73.8M | |
| Total Debt | $128.2M | $142.4M | $129.3M | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$70.3M | -$128.5M | -$46.9M | -$28M | $7.9M | |
| Cash From Investing | $79.7M | -$50.1M | $51.8M | $27.9M | $14.9M | |
| Cash From Financing | $14.5M | $135.3M | $16M | -$21.1M | $880K | |
| Free Cash Flow | -$71M | -$128.5M | -$46.9M | -$28M | $7.9M | |
AVDL
Sector
Market Cap
$784.6M
$36.5M
Price % of 52-Week High
42.54%
44.66%
Dividend Yield
0%
0%
Shareholder Yield
-0.49%
-0.9%
1-Year Price Total Return
-51.78%
-39.9%
Beta (5-Year)
1.570
0.774
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$8.46
200-day SMA
Sell
Level
$12.32
Bollinger Bands (100)
Sell
Level
7.68 - 12.04
Chaikin Money Flow
Buy
Level
33.9M
20-day SMA
Sell
Level
$8.18
Relative Strength Index (RSI14)
Sell
Level
45.74
ADX Line
Sell
Level
13.71
Williams %R
Neutral
Level
-55.102
50-day SMA
Sell
Level
$8.17
MACD (12, 26)
Sell
Level
0.00
25-day Aroon Oscillator
Buy
Level
44
On Balance Volume
Neutral
Level
135.8M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.8475)
Sell
CA Score
(Annual)
Level (-1.1498)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (3.8207)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (7)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.
Stock Forecast FAQ
In the current month, AVDL has received 7 Buy ratings 0 Hold ratings, and 0 Sell ratings. The AVDL average analyst price target in the past 3 months is $17.70.
-
Where Will Avadel Pharmaceuticals PLC Stock Be In 1 Year?
According to analysts, the consensus estimate is that Avadel Pharmaceuticals PLC share price will rise to $17.70 per share over the next 12 months.
-
What Do Analysts Say About Avadel Pharmaceuticals PLC?
Analysts are divided on their view about Avadel Pharmaceuticals PLC share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Avadel Pharmaceuticals PLC is a Sell and believe this share price will drop from its current level to $13.00.
-
What Is Avadel Pharmaceuticals PLC's Price Target?
The price target for Avadel Pharmaceuticals PLC over the next 1-year time period is forecast to be $17.70 according to 7 Wall Street analysts, 7 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is AVDL A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Avadel Pharmaceuticals PLC is a Buy. 7 of 7 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of AVDL?
You can purchase shares of Avadel Pharmaceuticals PLC via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Avadel Pharmaceuticals PLC shares.
-
What Is The Avadel Pharmaceuticals PLC Share Price Today?
Avadel Pharmaceuticals PLC was last trading at $8.11 per share. This represents the most recent stock quote for Avadel Pharmaceuticals PLC. Yesterday, Avadel Pharmaceuticals PLC closed at $8.12 per share.
-
How To Buy Avadel Pharmaceuticals PLC Stock Online?
In order to purchase Avadel Pharmaceuticals PLC stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Super Micro Stock Fall So Much?
Super Micro Computer (NASDAQ:SMCI) was once a highly popular stock…
Is Diamondback Energy a Good Stock to Buy?
Diamondback Energy (FANG) is a lesser-known diamond in the rough…
Stock Ideas
Buy
56
Is AAPL Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 37x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Sell
44
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 39x
Alerts
Buy
69
CNXC alert for Mar 28
Concentrix [CNXC] is up 42.45% over the past day.
Buy
74
SLNO alert for Mar 27
Soleno Therapeutics [SLNO] is up 37.64% over the past day.
Buy
68
WOR alert for Mar 27
Worthington Enterprises [WOR] is up 0.16% over the past day.
